ES2054949T3 - Precursores de dopamina. - Google Patents
Precursores de dopamina.Info
- Publication number
- ES2054949T3 ES2054949T3 ES89114012T ES89114012T ES2054949T3 ES 2054949 T3 ES2054949 T3 ES 2054949T3 ES 89114012 T ES89114012 T ES 89114012T ES 89114012 T ES89114012 T ES 89114012T ES 2054949 T3 ES2054949 T3 ES 2054949T3
- Authority
- ES
- Spain
- Prior art keywords
- dopamine precursors
- dopamine
- precursors
- parkinson
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- 239000002243 precursor Substances 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPUESTOS DE LA FORMULA (EN DONDE R,R1,R2 Y X TIENEN EL SIGNIFICADO INFORMADO EN LA ESPECIFICACION SE DESCRIBEN LOS PROCESOS PARA SU PREPARACION Y LAS COMPOSICIONES FARMACEUTICAS CONTENIENDOLOLOS COMO INGREDIENTE ACTIVO. LOS COMPUESTOS DE LA FORMULA I SE USAN EN EL TRATAMIENTO DEL MAL DE PARKINSON, DISFUNCIONES RENALES, DESCOMPENSACION CARDIACA E HIPERTENSION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT8821543A IT1226727B (it) | 1988-07-29 | 1988-07-29 | Farmaci precursori della dopamina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2054949T3 true ES2054949T3 (es) | 1994-08-16 |
Family
ID=11183351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES89114012T Expired - Lifetime ES2054949T3 (es) | 1988-07-29 | 1989-07-28 | Precursores de dopamina. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5013753A (es) |
| EP (1) | EP0352815B1 (es) |
| JP (1) | JPH0296556A (es) |
| AT (1) | ATE89547T1 (es) |
| DE (1) | DE68906609T2 (es) |
| ES (1) | ES2054949T3 (es) |
| IT (1) | IT1226727B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991001724A1 (en) * | 1989-07-27 | 1991-02-21 | G.D. Searle & Co. | Renal-selective prodrugs for the treatment of hypertension |
| PT1196414E (pt) * | 1999-06-25 | 2003-12-31 | Vertex Pharma | Pro-farmacos de inibidores carbamato de impdh |
| US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| DE102005022276A1 (de) * | 2005-05-13 | 2006-11-16 | Ellneuroxx Ltd. | Derivate von Dihydroxyphenylalanin |
| TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
| EP2021325A2 (en) * | 2006-05-09 | 2009-02-11 | AstraZeneca AB | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
| EP2112923A1 (en) * | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| GB0713189D0 (en) * | 2007-07-06 | 2007-08-15 | Proximagen Ltd | Amino acid derivatives |
| ES2322121B1 (es) * | 2007-12-10 | 2010-04-19 | Consejo Superior De Investigaciones Cientificas | Nuevos derivados de aminoacidos dicarboxilicos y su aplicacion en el tratamiento de enfermedades neurodegenerativas. |
| BR112012029326A2 (pt) | 2010-05-20 | 2017-08-08 | Astrazeneca Ab | processo para a preparação de animais olefínicas substituídas por arila |
| BR112015022896B1 (pt) | 2013-03-15 | 2022-08-23 | Chongxi Yu | Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson |
| ES2739536T3 (es) | 2014-10-21 | 2020-01-31 | Abbvie Inc | Profármacos de carbidopa y L-dopa y su uso para tratar la enfermedad de Parkinson |
| PT3713933T (pt) | 2017-11-24 | 2026-05-19 | H Lundbeck As | Novos profrmacos de catecolamina para utilizao no tratamento de doena de parkinson |
| JP6596483B2 (ja) * | 2017-12-28 | 2019-10-23 | テックフィールズ ファーマ カンパニー リミテッド | パ−キンソン病治療用の新規高透過薬物及びその組成物 |
| TW202031265A (zh) | 2018-11-15 | 2020-09-01 | 美商艾伯維有限公司 | 用於皮下投藥之醫藥調配物 |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US12391650B2 (en) | 2019-05-21 | 2025-08-19 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
| JP7641234B2 (ja) | 2019-05-21 | 2025-03-06 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ |
| WO2020234275A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
| EP3972600B1 (en) | 2019-05-21 | 2026-02-18 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
| MX2023010450A (es) * | 2021-03-10 | 2023-09-14 | Neuroderm Ltd | Composiciones liquidas estabilizadas que comprenden un conjugado de tirosina y levodopa, y usos de estas. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947590A (en) * | 1973-10-23 | 1976-03-30 | Abbott Laboratories | Compositions and methods of increasing renal blood flow with gamma-glutamyl amide of dopamine |
| US3891696A (en) * | 1973-11-02 | 1975-06-24 | Interx Research Corp | Novel, transient pro-drug forms of l-dopa |
| US4035507A (en) * | 1975-04-17 | 1977-07-12 | Interx Research Corporation | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease |
| US4031242A (en) * | 1975-09-11 | 1977-06-21 | Abbott Laboratories | Diacylated derivatives of γ-glutamyl dopamine |
| US4125626A (en) * | 1977-01-17 | 1978-11-14 | Mt. Sinai School Of Medicine Of The City University Of New York | Synthesis and use of L-γ-glutamyl-DOPA |
-
1988
- 1988-07-29 IT IT8821543A patent/IT1226727B/it active
-
1989
- 1989-07-28 AT AT89114012T patent/ATE89547T1/de not_active IP Right Cessation
- 1989-07-28 ES ES89114012T patent/ES2054949T3/es not_active Expired - Lifetime
- 1989-07-28 US US07/386,106 patent/US5013753A/en not_active Expired - Lifetime
- 1989-07-28 DE DE8989114012T patent/DE68906609T2/de not_active Expired - Fee Related
- 1989-07-28 JP JP1197894A patent/JPH0296556A/ja active Pending
- 1989-07-28 EP EP89114012A patent/EP0352815B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0296556A (ja) | 1990-04-09 |
| DE68906609D1 (de) | 1993-06-24 |
| EP0352815B1 (en) | 1993-05-19 |
| US5013753A (en) | 1991-05-07 |
| DE68906609T2 (de) | 1993-08-26 |
| IT8821543A0 (it) | 1988-07-29 |
| ATE89547T1 (de) | 1993-06-15 |
| EP0352815A1 (en) | 1990-01-31 |
| IT1226727B (it) | 1991-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2058291T3 (es) | Derivados de piperazinilo de las purinas e isosteros de las mismas como agentes hipoglucemicos. | |
| DK1157037T3 (da) | GCSF-konjugater | |
| BR0315547A (pt) | Derivados de quinolina como antagonistas de crth2 | |
| PT97689A (pt) | Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida | |
| AR028833A1 (es) | Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion | |
| TR200102020T2 (tr) | Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler. | |
| BRPI0409133A (pt) | formulações farmacêuticas contendo metilnaltrexona | |
| UY28510A1 (es) | Compuestos quimicos | |
| AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
| AR022860A1 (es) | Derivados de camptotecina que poseen actividad antitumoral | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| UY28271A1 (es) | Compuestos químicos | |
| ATE89547T1 (de) | Dopamin-vorlaeufer. | |
| UY30393A1 (es) | Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
| ES2011232T3 (es) | Composiciones farmaceuticas de piroxicam en soluciones acuosas y procedimiento para su preparacion. | |
| IT7819951A0 (it) | Solfonati attivi come erbicidi, procedimenti per la loro preparazione e composizioni che licontengono. | |
| IT1094585B (it) | Derivati di azolil-eteri,procedimento per la loro preparazone e loro impiego come fungicidi | |
| ES2058228T3 (es) | Compuestos activos sobre el sistema cardiovascular. | |
| ES2144154T3 (es) | Derivados de eritromicina a 9-0-oxima dotados de actividad antibiotica. | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| UY28687A1 (es) | Ligandos del receptor de acetilcolina nicotinica | |
| AR002272A1 (es) | Uso de amidas de fenilciclohexilcarboxilicos | |
| AR026451A1 (es) | Compuestos heterociclicos sililados | |
| ITMI931723A1 (it) | Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari | |
| ES2132283T3 (es) | Derivados n-heteroaril sustituidos de propanamida utiles en el tratamiento de enfermedades cardiovasculares. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 352815 Country of ref document: ES |